American Portfolios Advisors Altimmune, Inc. Transaction History

American Portfolios Advisors

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Mar 20, 2023	BUY	$3.94 - $11.77 $985 - $2,942	250 New	250 $2.93 Million
Q1 2022 Mar 21, 2023	BUY	$5.9 - $9.45 $1,475 - $2,362	250 New	250 $1.52 Million
Q4 2021 Mar 21, 2023	BUY	$8.69 - $12.48 $2,172 - $3,120	250 New	250 $2.29 Million
Q3 2021 Mar 22, 2023	BUY	$8.43 - $16.81 $2,107 - $4,202	250 New	250 $2.83 Million
Q2 2021 Mar 22, 2023	BUY	$9.85 - $16.46 $7,387 - $12,345	750 New	750 $7.39 Million
Q1 2021 Mar 22, 2023	BUY	$12.71 - $24.31 $9,532 - $18,232	750 New	750 $10.6 Million
Q4 2020 Mar 22, 2023	BUY	$7.84 - $14.22 $5,880 - $10,665	750 New	750 $8.46 Million
Q2 2020 Mar 24, 2023	SELL	$2.9 - $10.71 $2,900 - $10,710	-1,000 Closed	0 $0
Q1 2020 Mar 24, 2023	BUY	$1.69 - $3.8 $1,690 - $3,800	1,000 New	1,000 $3.21 Million
Q4 2019 Mar 24, 2023	BUY	$1.53 - $2.15 $1,530 - $2,150	1,000 New	1,000 $1.89 Million
Q2 2019 Mar 24, 2023	BUY	$2.19 - $3.4 $2,190 - $3,400	1,000 New	1,000 $2.38 Million
Q1 2019 Mar 24, 2023	BUY	$2.54 - $4.54 $2,286 - $4,086	900 Added 900.0%	1,000 $2.9 Million
Q3 2018 Mar 24, 2023	BUY	$4.27 - $26.23 $426 - $2,623	100 New	100 $440,000

185

39.2M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $373M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

Stay updated on American Portfolios Advisors with notifications on news.